A U.S. Food and Drug Administration advisory committee has recommended against the accelerated approval for AstraZeneca Plc’s (AZN) ovarian cancer drug olaparib based on mid-stage study results.

The FDA Oncologic Drugs Advisory Committee voted 11 to 2 that the current evidence from clinical studies does not support an accelerated approval for use of olaparib.

The investigational drug is indicated as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA (gBRCA) mutation, and who are in complete or partial response to platinum-based chemotherapy.

Continue Reading

READ FULL ARTICLE Curated publisher From RTT News